Navigation Links
Researchers reveal underlying mechanism of powerful chemotherapy for prostate cancer treatment
Date:9/17/2012

NEW YORK (Sept. 17, 2012) -- The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.

Most physicians and investigators believe that taxane chemotherapy (paclitaxel, docetaxel and cabazitaxel) just does one thing -- stop a cancer cell from dividing -- but the team of Weill Cornell scientists have revealed it acts much more powerfully and broadly, especially against prostate cancer.

"Taxanes are one of the best class of chemotherapy drugs that we can use to treat our cancer patients, but while they are effective against a wide range of tumors, they don't work in all of them, and often patients become resistant," says the study's senior investigator, Dr. Paraskevi Giannakakou, an associate professor of pharmacology in medicine and pharmacology and director of laboratory research for the Division of Hematology and Medical Oncology at Weill Cornell. "However, our new understanding of the precise action of taxanes in a cancer cell may help us overcome drug insensitivity or acquired resistance to the drugs and design therapies that can be used in combination with them to improve cancer control."

In their study, the researchers stress that investigators must shift their attention away from taxane's function during cell division to the drugs' effects on halting the everyday movement of proteins and protein-to-protein communication within cancer cells -- and to understanding how and why a cancer cell can still survive. Researchers suggest that cancers that are insensitive to taxanes -- or those that have become resistant to them -- may, for example, switch to alternate forms of "transportation" to shuttle proteins within cells in a way that does not depend on the cell's skeletal structure which is the target of taxane therapy.

Researchers showed in the study that the androgen
'/>"/>

Contact: Lauren Woods
law2014@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Researchers develop a new cell and animal model of inflammatory breast cancer
3. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
4. Researchers Find Gene Mutations That May Be a Key to Autism
5. Researchers find evidence of banned antibiotics in poultry products
6. NJ stroke researchers report advances in spatial neglect research at AAN Conference
7. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
8. Researchers Map Brain Regions Linked to Intelligence
9. Researchers ID Genes That May Determine Mental Illness
10. Researchers Develop Blood Test for Depression
11. University of Cincinnati researchers win $3.7M grant from US Department of Defense
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 When the mercury rises, heat ... driving engine, the heart, takes on a heavier load in ... July 2014 issue of the Harvard Men's Health Watch ... requires no more than knowing their limits and drinking enough ... going to be more sensitive to the heat," says Dr. ...
(Date:7/11/2014)... Angeles, CA (PRWEB) July 11, 2014 ... Sands today announces that he uses mini and full ... treatments offer the defining feature that distinguishes dental implants ... teeth in addition to the crowns. This alone prevents ... implants also offer advantages related to comfort, appearance ...
(Date:7/11/2014)... -- A new study challenges the widely held belief that ... Researchers analyzed more than 50 studies that examined drinking ... They found that those with a form of a gene ... The gene affects how a person,s body breaks down alcohol, ... Having this variant has been shown to lead to lower ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cancer researchers ... have a significant impact on how patients respond to ... for mesothelioma. Surviving Mesothelioma has the full story. ... , Researchers at the University of Ljubljana and the ... pemetrexed for different types of polymorphisms. They found ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Anterior Cruciate ... year, but the type of material used to create ... in the game, say researchers presenting their work today ... of Sports Medicine ( AOSSM ). , ... population, allografts (tissue harvested from a donor) fail more ...
Breaking Medicine News(10 mins):Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:A Little Alcohol May Not Be Good for Your Heart After All 2Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... Hello Kitty, the moon-faced cartoon cat turned global icon of ... yen (32,000 dollars) for the ultimate pampered pooch . ... and a cushion bearing Hello Kitty's face, will be put ... Sanrio Co. said. ,Sanrio designer Ikuko Shimizu launched ...
... high-risk of having a heart attack are unclear about when ... an ambulance , argue a group of heart specialists in ... who die from coronary heart disease have had previous heart ... Foundation shows that 40% of the general population would not ...
... new score for predicting the risk of heart disease gives ... at risk of developing the disease and which adults are ... study published on bmj.com today, estimates that in the general ... million adults under the age of 75 in Britain at ...
... number of studies have suggested that regular exercise reduces inflammation ... other diseases, such as diabetes its still not clear ... link exists, the nature of the relationship is by no ... and community health researchers at the University of Illinois provides ...
... a medical device company founded in 2004 to bring ... surgical markets, announced that vascular surgeons at the ... clinically use their novel high performance vascular sealant, ArterX(TM). ... a 74 year old man suffering from vascular insufficiency ...
... has constituted rapid response teams to combat diseases of all ... teams have been formed to combat both contagious and non-contagious ... (IDSP)," Madhya Pradesh health minister Ajay Vishnoi told IANS. ... 2004 with an objective to compile survey work and immediate ...
Cached Medicine News:Health News:High-risk Patients Need Better Guidance on What is and Isnt a Heart Attack 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 3Health News:Exercise Reduces Inflammation 2Health News:Exercise Reduces Inflammation 3Health News:Exercise Reduces Inflammation 4Health News:Tenaxis Medical Inc. Announces First Human Use of Vascular Sealant 2
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery company, ... it has raised A$19.3 million via a placement of ... , the U.S., Asia ... from a share purchase plan (SPP) to be offered ... be made in two tranches. "This capital ...
(Date:7/11/2014)... 11, 2014 On Thursday, ... 0.52%, the Dow Jones Industrial Average finished the day 0.42% ... down 0.41%. The losses were broad based as eight out ... 500 Health Care Sector Index ended the day at 711.88, ... last one month. Investor-Edge has initiated coverage on the following ...
(Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
... levels following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus ... tolerability comparable to ... - Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., ... of a 4-week Phase 1,clinical trial to evaluate two oral dose levels ...
... Duration of ... Neutropenia- ... Jan. 7 Maxygen, Inc.,(Nasdaq: MAXY ) today announced positive progress in ... the trial include the following:, -- Patients in the initial 10 ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 2Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 4
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
... Sprint Automated Urine Microscopy Analyzer (iQ200 Sprint) ... Series. The analyzer uses digital imaging and ... particles into 12 categories and quantitatively report ... time used to prepare and interpret urine ...
A flexible hematology platform:, 32 parameters, Automatic result validation, Cytology atlas included, CBC and 5+3 DIFF...
StarClose Clip Applier, (includes), Clip Applier, 6F Exchange Sheath, 6F Dilator, 0.038 50 cm J-Tip Guide Wire ...
Medicine Products: